Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

Figure 3

MicroRNA-125b, microRNA-205 and microRNA-424 deregulations confer letrozole and anastrozole resistance. (A) Microarray mean intensity values of the six microRNA (miR) probe sets commonly deregulated between Res-Let and Res-Ana cells. (B) Quantitative real-time PCR (RTQ-PCR) validation of miR-125b-5p-, miR-205-5p- and miR-424-3p-deregulated expression levels in Res-Let and Res-Ana cells versus MCF-7aro cells (mean ± SD from at least three independent experiments). (C) RTQ-PCR transfection efficiency validation in the MCF-7aro cells transfected with either the negative control of mimics, miR-125b-5p mimic, miR-205-5p mimic or (D) with either the negative control of inhibitor or miR-424-3p inhibitor (mean ± SD from at least three independent experiments). (E) Cell viability in response to letrozole in MCF-7aro cells transiently transfected with either the negative control of mimics, miR-125b-5p mimic, miR-205-5p mimic or (F) with the negative control of inhibitor or miR-424-3p inhibitor. (G) Cell viability in response to anastrozole in MCF-7aro cells transiently transfected with either the negative control of mimics, miR-125b-5p mimic, miR-205-5p mimic or (H) with either the negative control of inhibitor or miR-424-3p inhibitor. (E), (F), (G) and (H) are representative of at least three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test).

Back to article page